Cargando…

The VEGF-Receptor Inhibitor Axitinib Impairs Dendritic Cell Phenotype and Function

Inhibitors of VEGF receptor (VEGFR) signaling such as sorafenib and sunitinib that are currently used in the treatment of malignant diseases have been shown to affect immunological responses by inhibition of the function of antigen presenting cells and T lymphocytes. The VEGFR-inhibitor axitinib has...

Descripción completa

Detalles Bibliográficos
Autores principales:	Heine, Annkristin, Held, Stefanie Andrea Erika, Daecke, Solveig Nora, Riethausen, Kati, Kotthoff, Philipp, Flores, Chrystel, Kurts, Christian, Brossart, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4456373/ https://www.ncbi.nlm.nih.gov/pubmed/26042424 http://dx.doi.org/10.1371/journal.pone.0128897

Ejemplares similares

Spoilt for choice: different immunosuppressive potential of anaplastic lymphoma kinase inhibitors for non small cell lung cancer
por: Heine, Annkristin, et al.
Publicado: (2023)

Analysis of the anti-proliferative and the pro-apoptotic efficacy of Syk inhibition in multiple myeloma
por: Koerber, Ruth-Miriam, et al.
Publicado: (2015)

The PI3Kδ inhibitor idelalisib impairs the function of human dendritic cells
por: Braun, Christiane, et al.
Publicado: (2021)

Elotuzumab spares dendritic cell integrity and functionality
por: Schlaweck, Sebastian, et al.
Publicado: (2021)

Dexamethasone induced inhibition of Dectin-1 activation of antigen presenting cells is mediated via STAT-3 and NF-κB signaling pathways
por: Kotthoff, Philipp, et al.
Publicado: (2017)

RNA Vaccines in Cancer Treatment
por: Bringmann, Anita, et al.
Publicado: (2010)

Blastic plasmacytoid dendritic-cell neoplasia: a challenging case report
por: Koerber, Ruth-Miriam, et al.
Publicado: (2021)

Baseline immune signature score of Tregs × HLA-DR(+)CD4(+) T cells × PD1(+)CD8(+) T cells predicts outcome to immunotherapy in cancer patients
por: Mispelbaum, Rebekka, et al.
Publicado: (2022)

Successful Treatment of Refractory Squamous Cell Cancer of the Head and Neck with Nivolumab and Ipilimumab
por: Schwab, Katjana S., et al.
Publicado: (2018)

Implementing combinatorial immunotherapeutic regimens against cancer: The concept of immunological conditioning
por: Wolf, Dominik, et al.
Publicado: (2014)

Clinical and immunological effects of mRNA vaccines in malignant diseases
por: Heine, Annkristin, et al.
Publicado: (2021)

Vemurafenib as bridging therapy of hairy cell leukemia in a Jehovah’s Witness patient
por: Schlaweck, Sebastian, et al.
Publicado: (2021)

Two cases of EBV infection preceding lymphoma
por: Saal, Jonas, et al.
Publicado: (2022)

Red blood cell transfusions impact response rates to immunotherapy in patients with solid malignant tumors
por: Mispelbaum, Rebekka, et al.
Publicado: (2022)

G-quadruplexes: a promising target for cancer therapy
por: Kosiol, Nils, et al.
Publicado: (2021)

BG-flow, a new flow cytometry tool for G-quadruplex quantification in fixed cells
por: De Magis, Alessio, et al.
Publicado: (2021)

Evaluation of β-Catenin Inhibition of Axitinib and Nitazoxanide in Human Monocyte-Derived Dendritic Cells
por: Azeem, Waqas, et al.
Publicado: (2021)

Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics
por: Tortorici, Michael A., et al.
Publicado: (2010)

Long Term Remission and Cardiac Toxicity of a Combination of Ipilimumab and Nivolumab in a Patient With Metastatic Head and Neck Carcinoma After Progression Following Nivolumab Monotherapy
por: Schwab, Katjana S., et al.
Publicado: (2019)

Selenium substituted axitinib reduces axitinib side effects and maintains its anti-renal tumor activity
por: Fu, Ying, et al.
Publicado: (2022)

SARS-CoV-2 PrEP complicates antibody testing after vaccination: a call for awareness
por: Monin, Malte B., et al.
Publicado: (2022)

The Debate about Dendritic Cells and Macrophages in the Kidney
por: Gottschalk, Catherine, et al.
Publicado: (2015)

Axitinib in Metastatic Renal Cell Carcinoma
por: Mittal, Kriti, et al.
Publicado: (2012)

ATLAS trial of adjuvant axitinib in patients with renal cell carcinoma: subgroup analyses with focus on axitinib dosing and racial groups
por: Quinn, D.I., et al.
Publicado: (2021)

MicroRNA-146a reduces MHC-II expression via targeting JAK/STAT-signaling in dendritic cells after stem cell transplantation
por: Stickel, Natalie, et al.
Publicado: (2017)

Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers
por: Pithavala, Yazdi K., et al.
Publicado: (2010)

Axitinib for the Management of Metastatic Renal Cell Carcinoma
por: Escudier, Bernard, et al.
Publicado: (2012)

Axitinib: Newly Approved for Renal Cell Carcinoma
por: Tyler, Timothy
Publicado: (2012)

Design, Synthesis, and Biological Evaluation of Axitinib Derivatives
por: Wei, Na, et al.
Publicado: (2018)

Inhibition of Axitinib on Buspirone Metabolism in vitro and in vivo
por: Zhang, Bo-Wen, et al.
Publicado: (2022)

Impaired Retinal Circulation during Axitinib Treatment for Metastatic Renal Cell Carcinoma
por: Kimura, Masashi, et al.
Publicado: (2019)

Axitinib Improves Radiotherapy in Murine Xenograft Lung Tumors
por: Hillman, Gilda G., et al.
Publicado: (2014)

Axitinib Has Antiangiogenic and Antitumorigenic Activity in Myxoid Liposarcoma
por: Kerr, Lauren T., et al.
Publicado: (2016)

Axitinib in sequential therapy in metastatic renal cell carcinoma
por: Kuchar, Agata, et al.
Publicado: (2016)

Axitinib/pembrolizumab: Tumour-lysis-syndrome: case report
Publicado: (2020)

A Case Report with Severe Thrombocytopenia Induced by Axitinib
por: Koksal, Ulkuhan I., et al.
Publicado: (2020)

Axitinib and HDAC Inhibitors Interact to Kill Sarcoma Cells
por: Roberts, Jane L., et al.
Publicado: (2021)

Beyond the Checkpoint: Severe Axitinib-induced Liver Injury
por: Yeo, Yee Hui, et al.
Publicado: (2023)

Optimized Conformal Total Body Irradiation with VMAT Using a Linear-Accelerator-Based Radiosurgery Treatment System in Comparison to the Golden Standard Helical TomoTherapy
por: Köksal, Mümtaz, et al.
Publicado: (2023)

Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients
por: Fujiwara, Yutaka, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_104hnta7bajvqngphmorothmi7